These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 34052738)

  • 21. Proprotein Convertase Subtilisin/Kexin-Type 9 and Lipid Metabolism.
    Guo S; Xia XD; Gu HM; Zhang DW
    Adv Exp Med Biol; 2020; 1276():137-156. PubMed ID: 32705598
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potent Lys Patch-Containing Stapled Peptides Targeting PCSK9.
    Bourbiaux K; Legrand B; Verdié P; Mallart S; Manette G; Minoletti C; Stepp JD; Prigent P; Le Bail JC; Gauzy-Lazo L; Duclos O; Martinez J; Amblard M
    J Med Chem; 2021 Aug; 64(15):10834-10848. PubMed ID: 34266235
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure and Function of Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in Hyperlipidemia and Atherosclerosis.
    Lu X
    Curr Drug Targets; 2019; 20(10):1029-1040. PubMed ID: 30767742
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation.
    Weider E; Susan-Resiga D; Essalmani R; Hamelin J; Asselin MC; Nimesh S; Ashraf Y; Wycoff KL; Zhang J; Prat A; Seidah NG
    J Biol Chem; 2016 Aug; 291(32):16659-71. PubMed ID: 27284008
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis of Moracin C and Its Derivatives with a 2-arylbenzofuran Motif and Evaluation of Their PCSK9 Inhibitory Effects in HepG2 Cells.
    Masagalli JN; BasavanaGowda MK; Chae HS; Choi WJ
    Molecules; 2021 Mar; 26(5):. PubMed ID: 33801308
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of 2,3'-diindolylmethanes as a novel class of PCSK9 modulators.
    Winston-McPherson GN; Xie H; Yang K; Li X; Shu D; Tang W
    Bioorg Med Chem Lett; 2019 Aug; 29(16):2345-2348. PubMed ID: 31227343
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pseurotin A as a novel suppressor of hormone dependent breast cancer progression and recurrence by inhibiting PCSK9 secretion and interaction with LDL receptor.
    Abdelwahed KS; Siddique AB; Mohyeldin MM; Qusa MH; Goda AA; Singh SS; Ayoub NM; King JA; Jois SD; El Sayed KA
    Pharmacol Res; 2020 Aug; 158():104847. PubMed ID: 32438039
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential effects of red yeast rice, Berberis aristata and Morus alba extracts on PCSK9 and LDL uptake.
    Lupo MG; Macchi C; Marchianò S; Cristofani R; Greco MF; Dall'Acqua S; Chen H; Sirtori CR; Corsini A; Ruscica M; Ferri N
    Nutr Metab Cardiovasc Dis; 2019 Nov; 29(11):1245-1253. PubMed ID: 31439394
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peroxisome Proliferator-activated receptor γ activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression.
    Duan Y; Chen Y; Hu W; Li X; Yang X; Zhou X; Yin Z; Kong D; Yao Z; Hajjar DP; Liu L; Liu Q; Han J
    J Biol Chem; 2012 Jul; 287(28):23667-77. PubMed ID: 22593575
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis and biological evaluation of berberine derivatives as a new class of broad-spectrum antiviral agents against Coxsackievirus B.
    Zeng QX; Wang HQ; Wei W; Guo TT; Yu L; Wang YX; Li YH; Song DQ
    Bioorg Chem; 2020 Jan; 95():103490. PubMed ID: 31855821
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhanced circulating PCSK9 concentration by berberine through SREBP-2 pathway in high fat diet-fed rats.
    Jia YJ; Xu RX; Sun J; Tang Y; Li JJ
    J Transl Med; 2014 Apr; 12():103. PubMed ID: 24755036
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Berberine: Ins and outs of a nature-made PCSK9 inhibitor.
    Ataei S; Kesharwani P; Sahebkar A
    EXCLI J; 2022; 21():1099-1110. PubMed ID: 36381647
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PCSK9 inhibition for LDL lowering and beyond - implications for patients with peripheral artery disease.
    Gebauer K; Reinecke H
    Vasa; 2018 Apr; 47(3):165-176. PubMed ID: 29412075
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9.
    Seidah NG; Abifadel M; Prost S; Boileau C; Prat A
    Pharmacol Rev; 2017 Jan; 69(1):33-52. PubMed ID: 27920219
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Black Raspberry Extract Enhances LDL Uptake in HepG2 Cells by Suppressing PCSK9 Expression to Upregulate LDLR Expression.
    Song KH; Kim YH; Im AR; Kim YH
    J Med Food; 2018 Jun; 21(6):560-567. PubMed ID: 29569973
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Berberine inhibits dyslipidemia in C57BL/6 mice with lipopolysaccharide induced inflammation.
    Xiao HB; Sun ZL; Zhang HB; Zhang DS
    Pharmacol Rep; 2012; 64(4):889-95. PubMed ID: 23087140
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New Aromatic Compounds from the Fruiting Body of Sparassis crispa (Wulf.) and Their Inhibitory Activities on Proprotein Convertase Subtilisin/Kexin Type 9 mRNA Expression.
    Bang S; Chae HS; Lee C; Choi HG; Ryu J; Li W; Lee H; Jeong GS; Chin YW; Shim SH
    J Agric Food Chem; 2017 Aug; 65(30):6152-6157. PubMed ID: 28689410
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tanshinone IIA Modulates Low Density Lipoprotein Uptake via Down-Regulation of PCSK9 Gene Expression in HepG2 Cells.
    Chen HC; Chen PY; Wu MJ; Tai MH; Yen JH
    PLoS One; 2016; 11(9):e0162414. PubMed ID: 27617748
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An Unbiased Mass Spectrometry Approach Identifies Glypican-3 as an Interactor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR) in Hepatocellular Carcinoma Cells.
    Ly K; Essalmani R; Desjardins R; Seidah NG; Day R
    J Biol Chem; 2016 Nov; 291(47):24676-24687. PubMed ID: 27758865
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Series of Novel and Highly Potent Cyclic Peptide PCSK9 Inhibitors Derived from an mRNA Display Screen and Optimized via Structure-Based Design.
    Alleyne C; Amin RP; Bhatt B; Bianchi E; Blain JC; Boyer N; Branca D; Embrey MW; Ha SN; Jette K; Johns DG; Kerekes AD; Koeplinger KA; LaPlaca D; Li N; Murphy B; Orth P; Ricardo A; Salowe S; Seyb K; Shahripour A; Stringer JR; Sun Y; Tracy R; Wu C; Xiong Y; Youm H; Zokian HJ; Tucker TJ
    J Med Chem; 2020 Nov; 63(22):13796-13824. PubMed ID: 33170686
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.